Jefferies Downgrades Amicus Therapeutics, Inc. (FOLD) to Buy And Lowers Price Target Amid Takeover Developments

TheFly reported connected January 22 that Jefferies downgraded FOLD to Buy from Hold and lowered the terms people to $14.50 from $16. The institution got important pharmaceutical takeover involvement extracurricular of BioMarin, according to proxy records, but Jefferies does not expect immoderate much proposals.

Separately, past period connected December 19, BioMarin announced that it volition get Amicus Therapeutics, Inc. (NASDAQ:FOLD) for $14.50 per stock successful an all-cash transaction, valuing the institution astatine astir $4.8 billion. The acquisition adds 2 marketed therapies that are Galafold for Fabry illness and Pombiliti + Opfolda for Pompe disease, which generated $599 cardinal successful combined gross implicit the past 4 quarters.

Amicus Therapeutics, Inc. (NASDAQ:FOLD) is simply a biotechnology institution that america focused connected processing and commercializing innovative treatments for uncommon and orphan diseases. Its pipeline includes therapies for familial and metabolic disorders, specified arsenic Fabry disease, leveraging precision subject and patient‑centric solutions to amended long‑term wellness outcomes.

While we admit the imaginable of FOLD arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 12 Best Multibagger Stocks to Buy Heading into 2026 and 7 Best Rising Tech Stocks to Buy Now.

Disclosure: None.